Dahan Michel
SEC CIK 1669737 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| AKBA | Akebia Therapeutics, Inc. | SVP, COO | 672.1K | — | $263.1K | 11 | 2022-02-28 | 2024-05-13 |
Most active insiders at AKBA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Butler John P. | CEO, Pres, Dir | $86.6K | $474.4K |
| 2 | Grund Nicholas | Chief Commercial Off | — | $117.9K |
| 3 | Ostrowski Erik | SVP, CFO, CBO, Treas | — | $110.8K |
| 4 | Rucci Carolyn M. | SVP, CLO | — | $97.0K |
| 5 | Burke Steven Keith | SVP, Chief Medical Off | — | $94.0K |
| 6 | Malabre Richard C | SVP, CAO | — | $68.8K |
| 7 | FRIESON RON | Dir | — | — |
| 8 | Wolf Myles | Dir | — | — |
| 9 | Smith Cynthia | Dir | — | — |
| 10 | ADAMS ADRIAN | Dir | — | — |
Dahan Michel made no open-market trades at AKBA in the last 12 months.
Transactions 11
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2024-05-14 | 2024-05-13 | AKBA | Akebia Therapeutics, Inc. | Dahan Michel | SVP, COO | S - Sale | $1.26 | -34.8K | 672.1K | -5% | -$43.9K |
| 2024-03-01 | 2024-02-29 | AKBA | Akebia Therapeutics, Inc. | Dahan Michel | SVP, COO | S - Sale | $1.58 | -8,661 | 706.9K | -1% | -$13.7K | |
| 2024-02-29 | 2024-02-27 | AKBA | Akebia Therapeutics, Inc. | Dahan Michel | SVP, COO | S - Sale | $1.52 | -10.7K | 715.6K | -1% | -$16.3K | |
| D | 2024-02-02 | 2024-01-31 | AKBA | Akebia Therapeutics, Inc. | Dahan Michel | SVP, COO | A - Grant | $0.00 | +149.3K | 726.3K | +26% | $0 |
| D | 2023-05-25 | 2023-05-24 | AKBA | Akebia Therapeutics, Inc. | Dahan Michel | SVP, COO | A - Grant | $0.00 | +200.0K | 669.5K | +43% | $0 |
| D | 2023-05-25 | 2023-05-25 | AKBA | Akebia Therapeutics, Inc. | Dahan Michel | SVP, COO | S - Sale | $1.22 | -95.5K | 574.0K | -14% | -$116.5K |
| 2023-05-16 | 2023-05-12 | AKBA | Akebia Therapeutics, Inc. | Dahan Michel | SVP, COO | A - Grant | $0.00 | +200.0K | 469.5K | +74% | $0 | |
| M | 2023-03-03 | 2023-03-01 | AKBA | Akebia Therapeutics, Inc. | Dahan Michel | SVP, COO | S - Sale | $0.88 | -20.4K | 269.5K | -7% | -$18.0K |
| 2023-03-01 | 2023-02-27 | AKBA | Akebia Therapeutics, Inc. | Dahan Michel | SVP, COO | S - Sale | $0.81 | -10.1K | 289.9K | -3% | -$8,173 | |
| DM | 2022-03-02 | 2022-02-28+ | AKBA | Akebia Therapeutics, Inc. | Dahan Michel | SVP, COO | S - Sale | $2.16 | -21.5K | 302.1K | -7% | -$46.6K |
| D | 2022-03-02 | 2022-02-28 | AKBA | Akebia Therapeutics, Inc. | Dahan Michel | SVP, COO | A - Grant | $0.00 | +50.0K | 309.0K | +19% | $0 |
Purchase Sale Sale after option exercise All abbreviations